Washington, D.C. — Dr. Jay Bhattacharya, the director of the National Institutes of Health, faced intense scrutiny during a Senate hearing Tuesday as he defended proposed cuts to the agency’s budget amidst an ambitious reorganization plan initiated by the Trump administration. Lawmakers from both parties expressed deep concerns about the potential impacts on medical research and public health.

Senate Appropriations Chairwoman Susan Collins of Maine voiced strong opposition to the proposed budget, highlighting a nearly 40% cut to the National Institute of Aging and similar reductions across the agency’s initiatives. “As the senator representing the oldest state in the nation, this is a particular concern,” said Collins, stressing the urgency of the issue for many American families.

Collins further criticized the administration’s plans for capping indirect costs for universities, describing the move as misguided and detrimental to research efforts in the United States. “It’s causing scientists to leave for opportunities elsewhere, halting clinical trials and abandoning promising medical research,” she noted. A recent federal court ruling has temporarily paused these caps, yet the administration’s budget plans appear to rely on the anticipated savings from these changes.

During the questioning, Bhattacharya differentiated between the acknowledged budget cuts and various administrative decisions, asserting that some grant funding pauses predated his direct role. He acknowledged, however, that the agency had adapted its grant priorities, shifting away from what he termed “politicized science.”

Senator Tammy Baldwin of Wisconsin joined the critique, ardently opposing the proposed $18 billion reduction to the NIH’s budget. “This would equate to funding for 15,000 fewer research projects,” Baldwin argued, warning of the long-term repercussions on biomedical research. She expressed doubt that Congress would support the budget proposal but emphasized that it reflected the administration’s disturbing direction. “How is this proposal anything but intentionally sabotaging biomedical research?” she queried.

While advocates for Alzheimer’s research and representatives from the American Cancer Society filled the hearing room, Bhattacharya reiterated his willingness to collaborate with Congress on budgetary matters, emphasizing a need for more flexible spending in medical research.

The hearing underscored a significant divide between government priorities and the scientific community’s expectations, as legislators grapple with the implications of proposed cuts on both health care innovation and patient care. As discussions continue, stakeholders remain watchful of the evolving landscape of federally funded medical research.